occult clinically undetectable primary sites that would probably not be detected during life with diagnostic testing. Approximately 60% of clinically occult primary tumors were from the colon/rectum, lung, and pancreas. 2 Patients with known primary adenocarcinomas are now more treatable. Significant improvements in survival have been documented for various systemic therapies. [3] [4] [5] These data are unequivocal and derived from large randomized, prospective phase III studies (level I evidence). Treatments for patients with advanced cancers continue to improve, as shown by the recent introduction of several new and useful biologic targeted agents (trastuzumab, imatinib, erlotinib, bevacizumab, cetuximab, sorafenib, sunitinib, lapatinib, and tensirolimus), alone or with cytotoxics.
Current survival data, including median, 1-, 2-, and 3-year survivals for patients with metastatic colon/rectum, 3, 6, 7 non-small cell lung, 4, [8] [9] [10] [11] pancreatic, 5, [12] [13] [14] and unknown primary carcinomas, are shown in Table 2 . The use of bevacizumab 3, 4 (colon/ rectum, non-small cell lung) and erlotinib 5 (pancreas) combined with cytotoxic chemotherapy in selected patients has shown improved survival over chemotherapy alone.
Because approximately 60% of patients with unknown primary carcinomas harbor a "treatable" occult primary carcinoma, some of these patients should benefit from the same treatments for patients with known primary tumors. This is particularly understandable if sometime during the course of their disease, patients with unknown primary carcinomas undergo various sequential combination regimens containing cisplatin or carboplatin, taxanes, gemcitabine, irinotecan, 5-fluorouracil, oxaliplatin, and bevacizumab/erlotinib.
No level I evidence proves that any form of chemotherapy versus best supportive care improves survival for these patients. However, considerable aggregate data (level II evidence) make a compelling argument that regimens developed in the past several years have improved survival for these patients.
Retrospective Survival Review
A review of historical survival data from several large series of patients seen over many decades provides a better understanding of the natural history and survival for patients with unknown primary cancer. [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] Data in Table 3 are retrospective and associated with all the known flaws of these types of reviews. Some patients were near death at diagnosis and others underwent no systemic therapy. Furthermore, many of these series contained some patients now known to be in favorable subsets. These historical series comprise Table 3 , patients with epidermoid or squamous carcinomas (often in neck nodes) and welldifferentiated neuroendocrine carcinoma (usually carcinoid) of unknown primary site had prolonged survivals (median approximately 20 months; 1-year, 65%; and 5-year, 30%). All remaining patients represented had very poor survival with an estimated 1-year survival of 12%; survival at 2 years was extremely unusual. Although these data had the known flaws associated with retrospective data, they provide a reasonable estimate of the very poor survival of these patients in the past.
Prospective Clinical Trials: 1964-2000
In the past, chemotherapy of various types produced low response rates, very few complete responses, and even rarer long-term survivals. A review of older prospective chemotherapy trials involving 1515 patients from 45 phase II trials reported from 1964 to 2002 1 showed a response rate of approximately 20% and a median survival of approximately 6 months. Survival at 2 years and beyond was rarely reported and progression-free survival beyond 2 years was not reported.
Only 4 small randomized phase II studies were reported. 25 Two randomized comparisons of regimens with or without cisplastin showed no difference in median survival. A third randomized trial showed the superiority of cisplatin, mitomycin C, and epirubicin compared with mitomycin C alone (median survival, 9.4 vs. 5.4 months). The fourth trial compared cyclophosphamide, methotrexate, and 5-fluorouracil with doxorubicin and mitomycin C. The response rate and median survival favored the doxorubicin-based regimen (36% vs. 5%; 4.5 vs. 1.7 months). Survival beyond 1 year was not reported.
Several factors should be considered when viewing these data. The studies were small, large randomized phase III comparisons are lacking, and long-term survival was not reported from any study. Many of these studies included some patients with favorable subsets. These results all reflect older chemotherapy and none included an arm for best supportive care. The patients were not evaluated or stratified in reference to sites of metastasis (nodal vs. visceral), performance status, sex, age, or other now-known prognostic factors. No convincing evidence showed that survival was prolonged by any therapy.
Prospective Clinical Trials Review After 2000
Several new cytostatic drugs with rather broad-spectrum antineoplastic activity and targeted mechanismbased therapies have recently improved standard treatment for patients with several common advanced epithelial cancers. Some drugs include the taxanes, gemcitabine, irinotecan, vinorelbine, topotecan, oxaliplatin, and several biologic targeted agents (including bevacizumab and erlotinib).
The gemcitabine, irinotecan, capecitabine, oxaliplatin, and bevacizumab/erlotinib into the first-, second-, or third-line therapy for 692 patients (most with good performance status) with carcinoma of an unknown primary site. One additional phase III randomized, prospective first-line trial is in progress comparing paclitaxel, carboplatin, and etoposide with gemcitabine and irinotecan, with 185 patients accrued. Only patients with carcinoma (any histology) who were not defined in a favorable subset were eligible for the first-line trials. All patients underwent a standard evaluation to detect a primary.
The chemotherapy regimens for the first 5 phase II MPCRN studies (396 previously untreated patients) were as follows: 1) paclitaxel, carboplatin, and etoposide (71 patients); 26 2) docetaxel, cisplatin (26 patients); 27 3) docetaxel and carboplatin (47 patients); 27 4) paclitaxel, carboplatin, and gemcitabine (120 patients); 28 and 5) paclitaxel, carboplatin, and etoposide followed by gemcitabine and irinotecan (132 patients). 29 The response rate for all patients was 30% (107 of 353 evaluable patients), with 85 (24%) partial and 22 (6%) complete responders. With a minimum and maximum follow-up of 2.5 and 9.5 years, respectively, the median survival was 9.1 months. The 1-, 2-, 3-, 5-, 8-, and 10-year survivals were 38%, 19%, 12%, 10%, 8%, and 8%, respectively (Figure 1) . 30 The median progression-free survival was 5 months and the 1-, 2-, 3-, 5-, 8-, and 10-year progression-free survival was 17%, 7%, 5%, 4%, 3%, and 3%, respectively. 30 The toxicity of all regimens was generally moderate, primarily myelosuppression. A total of 8 (2%) treatment-related deaths occurred.
Long-term follow-up of the 264 patients in the first 4 trials is as follows: minimum follow-up was 4.5 years (maximum 9.5 years), median survival was 10.2 months, and the 1-, 2-, 3-, 5-, 8-, and 10-year survivals were 41%, 24%, 15%, 11%, 8%, and 8%, respectively. 30 The actuarial survival for the 428 additional patients treated in 5 subsequent phase II trials and 185 patients in an ongoing phase III trial look similar. No significant survival differences were seen between the survival curves of first-line phase II studies. The central element in evaluating therapy for these patients has been survival at 1 year and beyond.
The FDA approved bevacizumab (an inhibitor of vascular endothelial growth factor) combined with chemotherapy for selected patients with advanced colorectal, non-small cell lung, and breast carcinomas, and erlotinib (an inhibitor of the epidermal growth factor receptor) for advanced non-small cell lung and pancreatic carcinomas. The MPCRN recently reported a phase II trial of bevacizumab/erlotinib in 51 patients with unknown primary carcinoma; 31 37 underwent previous chemotherapy and 14 were previously untreated but all had poor prognostic features (advanced liver metastasis, bone metastasis, or ≥ 3 visceral sites of involvement). All received bevacizumab 10 mg/kg intravenously every 2 weeks along with erlotinib 150 mg orally daily, and 47 underwent at least 8 weeks of therapy. Among patients undergoing treatment, 5 (10%) experienced a partial response and 29 (61%) had stable disease (many with some tumor shrinkage). Median survival was 7.4 months and 1-year survival was 33%. Patients tolerated this therapy relatively well (grade 3/4 toxicity of any type < 10%, except fatigue at 16%). Median and 1-year survivals seem superior to secondline chemotherapy and are similar to early results of many recent first-line chemotherapy trials. These results prompted an ongoing MPCRN phase II study of the 4-drug combination of paclitaxel/carboplatin plus bevacizumab/erlotinib in previously untreated patients.
Analysis of all previously untreated patients in the MPCRN trials shows no difference in survival for patients with adenocarcinomas versus those with poorly differentiated carcinomas. Women survived longer than men, and those with ECOG performance status 0 or 1 lived longer than those with performance status 2. analyses identified poor performance status, elevated serum lactate dehydrogenase, low serum albumin, and liver metastases as major independent negative prognostic factors. [32] [33] [34] It now seems that these factors can separate patients into at least 2 groups with significantly different survivals after therapy (median survival, 4 vs. 12 months), and additional prospective validation of these results is warranted. Prognostic factors are important in assessing the impact of a treatment.
Several other investigators have also reported on phase II trials since 2000 (Table 4 ). These trials usually involved the newer cytotoxic drugs, including platinum-, paclitaxel-, docetaxel-, gemcitabine-, irinotecan-, and vinorelbine-based regimens. 1, 30, [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] [45] [46] [47] In 12 phase II studies (530 total patients), patients with well-recognized favorable prognostic factors were excluded, and most patients had multiple sites of metastases, often with liver, bone, and lung involvement. A minority of the patients (about 15%) had poor functional status (ECOG = 2). Although clinical characteristics and pathology were variable, most patients in these studies (2000) (2001) (2002) (2003) (2004) (2005) (2006) (2007) had unfavorable prognostic features, and represent a relatively similar group. The primary end points were usually response rate or median survival. The median survivals (approximately 9 months; range, 6-13.6 months) are very similar to those in the MPCRN trials. Furthermore, survival at 1 year reported by all 12 trials ranged from 25% to 52% (mean, 34.6%) and survival at both 1 and 2 years was also reported by 8 of these studies, 35, 37, [39] [40] [41] [42] 46 ,47 including 405 patients. Survival at 1 and 2 years ranged from 26% to 52% (mean, 37%) and 9% to 20% (mean, 14%), respectively. Only 1 study reported a 3-year survival rate of 11%. 40 These recent data are very similar, although with shorter follow-up, to the 396 patients reported and previously discussed MPCRN studies, and document survival of a small minority of patients at 2 and 3 years (Table 4 ). Survival at 2 years and beyond has not been previously reported, and these data support progress in the therapy of these patients.
The efficiency of these therapies as assessed in relatively small clinical trials is best seen and documented at 1-, 2-, and 3-year survival end points. Fewer than 50% of the patients survive for 1 year; consequently, important and perhaps significant improvements in survival beyond 1 year cannot be appreciated when comparing only median survival data. Unless the trial is of phase III design and very large, concluding that a new therapy is not better based on lack of differences in median survival alone may be erroneous. After a particular treatment, 1-, 2-, and 3-year survival rates may be superior, but the median survival may not significantly change. Although survival is generally not the appropriate end point for phase II studies, this is all that is currently available to evaluate. Long-term survival data from several hundred patients in MPCRN studies and the 1-and 2-year survivals of several hundred patients recently reported by others are encouraging. Initial results with the targeted combination of bevacizumab/erlotinib are also provocative, 31 and warrant further study of biologic targeted agents combined with chemotherapy.
Survival reported from multiple recent phase II studies of these patients, most with unfavorable prognostic features, receiving the newer cytotoxic drugs, seem superior to not only the historical retrospective control data but also the combined data from multiple previous prospective clinical trials reported from 1964 to 2002. Large prospective, randomized phase III trials could provide definitive confirmation, but a no-treatment control (best supportive care) arm study will doubtfully ever be completed. Furthermore, the use of combined clinical, pathologic, and molecular profiling data is likely to be a more rational framework to design future clinical trials, rather than using empirically derived chemotherapy regimens.
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Conclusions
Is progress being made in the treatment of carcinoma of unknown primary site? These data reported in this article, including the documentation of long-term survival in a minority of patients in the past decade, provide a solid argument for progress. When also considering that several of these patients harbor occult carcinomas from the colon, rectum, pancreas, lung, kidney, breast, and other treatable sites, the argument is strengthened even further. Many common patients with unknown primary adenocarcinoma who are not in a previously defined favorable subset now experience significant clinical benefit and survival from the new drug combinations. Survival for these patients now compares favorably to that of several other patients with known metastatic primary carcinomas, including those with pancreatic and non-small cell lung carcinomas.
Much more improvement is needed, but the question of whether progress has been made in the therapy for these patients is no longer a relevant clinical question. More important questions are whether molecular profiling of a metastatic lesion will enable the primary site to be defined, and whether patients with primary sites identified through molecular profiling will respond to site-directed therapy and experience similar survival to those with a known primary site. Both questions should be answered in the next few years, and hopefully a better molecular understanding of each patient's individual neoplasm, when used with clinical and pathologic findings, will also lead to more specific and effective therapy.
